JRA-H-Fullcolor.png

 

March 3, 2021
by Kevin Hennegan

Understanding the purpose of an IND

Opening an Investigational New Drug (IND) application dossier can allow a sponsor to take advantage of the FDA’s drug development expertise and ensure the development program will meet the agency’s expectations at the time of the marketing application.

In a webinar replay, Veristat experts explore the minimum required content for an IND submission and the strategic considerations for developing more than the minimum necessary data before filing an IND.

View the webinar replay to help you better understand:
  • Drug development overview
  • Purpose of an IND
  • When do you have enough data?
  • Value of a pre-IND meeting
Kevin Hennegan is a senior regulatory strategist at Veristat. 
×

Welcome to the new RAPS Digital Experience

We have completed our migration to a new platform and are pleased to introduce the updated site.

What to expect: If you have an existing login, please RESET YOUR PASSWORD before signing in. After you log in for the first time, you will be prompted to confirm your profile preferences, which will be used to personalize content.

We encourage you to explore the new website and visit your updated My RAPS page. If you need assistance, please review our FAQ page.

We welcome your feedback. Please let us know how we can continue to improve your experience.